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ABSTRACT
Recent identification of a mutation in the EGF gene that causes isolated recessive hypomagnesemia led
to the finding that EGF increases the activity of the epithelial magnesium (Mg2) channel transient
receptor potential M6 (TRPM6). To investigate the molecular mechanism mediating this effect, we
performed whole-cell patch-clamp recordings of TRPM6 expressed in human embryonic kidney 293
(HEK293) cells. Stimulation of the EGF receptor increased current through TRPM6 but not TRPM7. The
carboxy-terminal -kinase domain of TRPM6 did not participate in the EGF receptor–mediated increase
in channel activity. This activation relied on both the Src family of tyrosine kinases and the downstream
effector Rac1. Activation of Rac1 increased the mobility of TRPM6, assessed by fluorescence recovery
after photobleaching, and a constitutively active mutant of Rac1 mimicked the stimulatory effect of EGF
on TRPM6 mobility and activity. Ultimately, TRPM6 activation resulted from increased cell surface
abundance. In contrast, dominant negative Rac1 decreased TRPM6 mobility, abrogated current devel-
opment, and prevented the EGF-mediated increase in channel activity. In summary, EGF-mediated
stimulation of TRPM6 occurs via signaling through Src kinases and Rac1, thereby redistributing endo-
membrane TRPM6 to the plasma membrane. These results describe a regulatory mechanism for trans-
epithelial Mg2 transport and consequently whole-body Mg2 homeostasis.
J Am Soc Nephrol 20: 78–85, 2009. doi: 10.1681/ASN.2008030327
Recently we described a mutation in the EGF gene,
encoding pro-EGF, which is responsible for a rare
form of renal magnesium (Mg2) wasting, isolated
recessive hypomagnesemia.1 A link between a defect
in EGF and renalMg2wastingwasmade by demon-
strating that pro-EGF is expressed in the distal convo-
luted tubule (DCT), where regulated transcellular
Mg2 reabsorption occurs via transient receptor po-
tentialM6 (TRPM6). Furthermore, supernatant from
the basolateral compartment of polarized epithelial
cells expressing pro-EGFwas able to activate TRPM6,
whereas supernatant fromcells expressing themutant
pro-EGF was unable to. The EGF receptor (EGFR/
ErbB1) is expressed in the basolateral membrane of
DCT, suggesting an autocrine/paracrine activation of
TRPM6 by EGF through its receptor. This has not
been confirmed, however; neither have themolecular
details of this activation been elucidated.
EGFR activation mediates its downstream effects
via numerous signaling cascades, including the extra-
cellular signal–regulated kinase (ERK) limbof themi-
togen-activated protein kinase (MAPK) superfamily,
protein kinase A (PKA), protein kinase C (PKC),
phosphoinositide 3-kinase (PI3K), and the phospho-
lipases C andD pathways.2 Activation of the EGFR in
DCT could therefore result in phosphorylation and
consequently activation of the previously described
target proteins. That EGFR signaling is implicit to
Mg2 homeostasis is further supported by the obser-
vation that patients treated with cetuximab, a mAb
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directed against the EGFR, develop hypomag-
nesemia1,3,4; however, the signaling pathway(s) down-
stream of EGFR activation, which stimulates TRPM6-
mediatedMg2 influx, remains to be determined.
The aim of this study was to ascertain the down-
stream signaling events, after EGFR engagement,
and ultimately the mechanism responsible for in-
creased TRPM6 activity. Elucidation of the molecu-
lar details responsible for EGFR-mediated stimula-
tion of TRPM6 will facilitate the development of
treatments for hypomagnesemia in general and dur-
ing cetuximab treatment. Using electrophysiologic
measurements in combination with biochemical
and live cell imaging techniques, we provide evi-
dence that EGF stimulates TRPM6 through the spe-
cific activation of the EGFR. This activates the Src
family of tyrosine kinases and the small Rho-GT-
Pase, Rac1, which results in a redistribution of vesic-
ular TRPM6 to the plasma membrane.
RESULTS
EGF Activates TRPM6 Current in HEK293
The presence of the EGFR was first confirmed in
HEK293 cells by immunoblotting, where it was de-
tected as a single immunopositive band with the ex-
pected molecular size of 170 kD (Figure 1A). Thus,
HEK293 cells provide an excellent model to study
the effect of EGF on TRPM6 activation. TRPM6 has
been expressed and characterized in this model sys-
tem, where it is detectable at the appropriate molec-
ular weight of 230 kD (Figure 1B).5We then assessed
the effect of EGF on TRPM6 current activity using whole-cell
recordings. We analyzed all time courses at80 and80 mV
for a 200-s period. EGF preincubation stimulated TRPM6 cur-
rent by 34 6 and 65 8% at80 and80mV, respectively,
compared with TRPM6 current in the absence of EGF (Figure
1, C and D). TRPM6 displayed an outwardly rectifying cur-
rent–voltage relation with a reversal potential close to 0 mV.
This was unaltered by EGF pretreatment (Figure 1E).
EGF-Stimulated TRPM6 Current Is Specifically
Mediated by the EGFR
To address whether the stimulatory action of EGF was specific to
activationof theEGFR,weadded the receptor antagonistAG1478
(also named tyrphostin) before treatment with EGF. Incubation
of TRPM6-expressing HEK293 cells with AG1478 prevented the
EGF stimulatory effect (Figure 2A). To confirm that EGFR stim-
ulation mediated the observed increase in TRPM6 current, we
used a specific tyrosine kinase receptor inhibitor, RG13022, to
block EGFR activation.6 After a 10-min exposure, EGF failed to
elicit an increase in TRPM6 activity (Figure 2B). In fact, incuba-
tion with either of these compounds reduced baseline TRPM6
activity (Figure2,AandB).WealsoexaminedTRPM7, theclosest
homologue of TRPM6, for an EGF-mediated increase in activity.
Consistentwith the notion that EGFR engagement by EGF is spe-
cific for TRPM6 activation, treatment with EGF did not affect
TRPM7 activity (Figure 2C).
Stimulation of TRPM6 by EGF Does not Require the
-Kinase Domain
TRPM6 uniquely encompasses an -kinase domain with a
channel. To determine whether the -kinase domain is neces-
sary for EGFR-mediated stimulation of TRPM6 activity, we
treated HEK293 cells transiently expressing an -kinase–trun-
cated TRPM6 mutant (TRPM6 -kinase)7 with EGF and sub-
jected them to whole-cell recordings. EGFR stimulation by
EGF was able to increase TRPM6 channel activity, even in the
absence of the -kinase domain. EGF increased the current in
TRPM6 -kinase transfected cells by 75 11 and 73 8% at
80 and80 mV, respectively (Figure 3A).
Stimulation of TRPM6 by EGF Involves Both Src-Family
Kinases and MAPK
Src family tyrosine kinases, including Fyn and Lyn, are impor-
tant downstream signaling intermediates of the EGFR. They
Figure 1. EGF treatment of HEK293 cells stimulates TRPM6 current. (A)
EGFR protein expression in HEK293 cells by immunoblot analysis. (B) Immu-
noblot of TRPM6, using the HA tag, in transiently transfected HEK293 cells.
(C and D) Time course of the current development (pA/pF) at80 mV (C) and
80 mV (D) of TRPM6 transfected HEK293 cells with (Œ) or without (F) EGF
pretreatment (10 nM, 30 min, 37C) and empty vector–transfected HEK293
cells with (‚) or without (E) EGF pretreatment (n  11 to 15 cells). (E)
Representative current–voltage relations of TRPM6-transfected HEK293 cells
with (Œ) or without (F) EGF pretreatment and mock-transfected HEK293 cells
with (‚) or without (E) EGF pretreatment after 200 s.
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are also known to regulate ion channel activity.8 We therefore
examined whether Src-family tyrosine kinases were necessary
for TRPM6 activation by EGF. Preincubationwith PP2, a com-
pound that selectively inhibits Src kinases,9 prevented the stim-
ulatory effect of EGF, whereas its inactive analog, PP3, failed to
prevent EGF from stimulating TRPM6 activity (Figure 3B).
Next, we conducted a series of experiments to identify
which signaling pathway(s), downstream of the Src family ki-
nases, is necessary for TRPM6 activation. The involvement of
phospholipase C (PLC) was excluded using the PLC inhib-
itor U73122 and its inactive analog, U73343 (Figure 3B). We
then evaluated the putative role of the MEK1/2 and ERK1/2
limb of the MAPK superfamily. To this end, we preincubated
HEK293 cells with selective inhibitors of MEK1/2 and ERK1/2
activation, UO126 and PD98059, respectively. Treatment with
either UO126 or PD98059 prevented EGF from increasing
Figure 2. EGFR stimulation by EGF mediates TRPM6 current
increase. (A) Time course of the TRPM6 current development
(pA/pF) at 80 mV (in transiently transfected HEK293 cells) pre-
treated with AG1478 (tyrphostin, 1 M, 1 h) alone (‚) or before
EGF pretreatment (Œ) in comparison with nontreated (E) or EGF-
treated (F) cells (n  9 to 13 cells). (B) Time course of TRPM6
current development (pA/pF) at80 mV in transiently transfected
HEK293 cells pretreated with RG13022 (tyrosine kinase inhibitor,
50 M, 10 min) alone () or before EGF pretreatment () relative
to nontreated (E) or EGF-treated (F) cells (n  11 to 14 cells). (C)
Time course of the TRPM7 current development (pA/pF) at 80
mV after transient transfection of HEK293 cells with (F; n  21) or
without (E; n  16) EGF pretreatment and empty vector–trans-
fected HEK293 cells with (Œ) or without () EGF pretreatment (n
9 to 14 cells).
Figure 3. EGF mediates an Src-family kinase and MAPK-depen-
dent activation of TRPM6 independent of the -kinase domain.
(A) Histogram summarizing the current density (pA/pF) at80 mV
and 80 mV after 200 s in mock-transfected () or TRPM6 -ki-
nase–transfected (f) HEK293 cells in the presence or absence of
EGF as indicated. *P  0.05 versus cells transfected with -kinase
in the absence of EGF treatment (n  13 to 19 cells). (B) Histo-
gram summarizing the averaged current density (pA/pF) at 80
mV and 80 mV after 200 s, of TRPM6-transfected HEK293 cells,
pretreated with PP2 (5 M, 10 min), PP3 (5 M, 10 min), U73122
(10 M, 15 min), U17343 (10 M, 15 min), PD98059 (15 M, 25
min), UO126 (50 M, 25 min), or forskolin (10 M, 15 min) without
() or with (f) EGF pretreatment (10 nM, 30 min). *P  0.05
versus TRPM6 current in the absence of EGF treatment (n  9 to
25 cells).
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TRPM6 activity, implicating the ERK1/2 pathway in
this signaling cascade (Figure 3B). None of these
agents had an effect on TRPM6 in the absence of
EGF. Stimulation of ERK1/2 by the EGFR is pre-
ceded by Raf-1 activation, an event that can be
blocked by PKA.10 To confirm that ERK1/2 activa-
tion was necessary for the EGF-mediated increase in
TRPM6 activity, we pretreated TRPM6-transfected
HEK293 cells with forskolin, thereby activating
PKA. Application of forskolin had no effect on
TRPM6 current; it did, however, prevent EGF-me-
diated activation (Figure 3B). These findings sup-
port the conclusion that TRPM6 activation after
EGFR engagement is mediated via activation of the
MAPK pathway.
Stimulation of TRPM6 by EGF Depends on
PI3K and Rac1
A downstream target of Src-family kinases is the
PI3K/Akt pathway. To address whether PI3K is in-
volved in the EGF-mediated stimulation of TRPM6,
we preincubated cells with the PI3K inhibitor
LY294005 or wortmannin. Preincubation with ei-
ther compound prevented the EGF-induced activa-
tion of TRPM6 (Figure 4A). Neither compound al-
tered the TRPM6 current when used in isolation
(data not shown). A common PI3K effector, impli-
cated in cytoskeletal remodeling and membrane
traffic, is Rac1.11–13 We therefore sought to ascertain
whether modulation of Rac1 activity would alter
baseline or the EGF-mediated increase in TRPM6
current. HEK293 cells were transiently co-trans-
fected with either a dominant negative mutant of
Rac1 (Rac1-T17N) and TRPM6 or a constitutively
active mutant of Rac1 (Rac1-G12V) and TRPM6
and then subjected to patch-clamp analysis. Control
cells were transiently co-transfected with empty vec-
tor and TRPM6. Cells coexpressing Rac1-T17N and
TRPM6 displayed significantly decreased TRPM6
currents compared with TRPM6-transfected cells
(Figure 4, B and C). In these cells, EGF pretreatment
did not restore TRPM6 current. In contrast, cells
co-transfected with Rac1-G12V and TRPM6 exerted
a significant increase in TRPM6 current (Figure 4, B
and C). The addition of EGF to HEK293 cells coexpressing
Rac1-G12V and TRPM6 did not further increase the TRPM6
current.
Activation of Rac1 can induce actin cytoskeletal rearrange-
ments. To assess whether this downstream effect of Rac1 was
responsible for the EGF-mediated activation of TRPM6, we
incubated the cells with cytochalasin D, alone or in combina-
tion with EGF, before obtaining whole-cell recordings. Cy-
tochalasin D pretreatment alone inhibited TRPM6 activity;
however, it failed to prevent the stimulation of TRPM6 activity
by EGF (Figure 4D).
EGF Increases Cell Surface Expression of TRPM6
Implicit to the observed alteration in TRPM6 activity by
Rac1 is the notion that EGFR signaling promotes the mobil-
ity of TRPM6, presumably by redistributing endomem-
brane channels into the plasma membrane. To this end, we
measured the mobility of TRPM6 in HEK293 cells. This was
accomplished with a GFP-fused TRPM6 construct and the
imaging technique fluorescence recovery after photo-
bleaching (FRAP). GFP-TRPM6 can be expressed and de-
tected in HEK293 cells by immunoblotting and fluorescence
microscopy (Figure 5, A and B). We evaluated the electro-
Figure 4. Stimulation of TRPM6 by EGF depends on PI3K, Rac1, and the
actin cytoskeleton. (A) Time course of the current development (pA/pF) at
80 mV of TRPM6-transfected HEK293 cells pretreated with wortmannin (10
nM, 20 min; Œ) or LY492005 (50 M, 20 min; ) before treatment with EGF.
For comparison, cells that were not treated at all (E) or treated just with EGF
(F) are included (n  9 to 13 cells). (B) Time course of the current develop-
ment (pA/pF) at 80 mV of TRPM6 and empty vector (circles), TRPM6 and
Rac1-G12V (triangles), and TRPM6 and Rac1-T17N (diamonds) transfected
HEK293 cells, pretreated (filled symbols) or not (open symbols) with EGF (n
13 to 19 cells). (C) Histogram summarizing the current density (pA/pF) at80
and 80 mV of TRPM6 and empty vector (Control), TRPM6 and Rac1-T17N
(T17N), and TRPM6 and Rac1-G12V (G12V) transfected HEK293 cells pre-
treated or not with EGF as indicated. , Experimental conditions in which
HEK293 cells were transfected with the empty vector; f, HEK293 cells
transfected with TRPM6 in the absence or presence of Rac1 mutants. *P 
0.05 versus TRPM6 current in empty vector–transfected, nontreated condi-
tions (n  13 to 19 cells). (D) Histogram summarizing the current density
(pA/pF) at 80 and 80 mV of TRPM6-transfected HEK293 cells pretreated
or not with EGF or cytochalasin D (CytD; 10 M, 40 min) as indicated. ,
Experimental conditions in which HEK293 cells were transfected with empty
vector; f HEK293 cells transfected with TRPM6. *P  0.05 versus TRPM6
current under nontreated conditions (n  14 to 16 cells).
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physiologic characteristics of GFP-TRPM6 by patch-clamp
analysis, and they displayed a similar baseline and EGF-
stimulated current (data not shown). As is evident from
Figure 5, C and E, EGF treatment increased both the rate
and the fraction of endomembrane TRPM6 that is mobile.
That Rac1 alters the mobility of TRPM6 was further sup-
ported by repeating these measurements after co-transfec-
tion with either Rac1-G12V, the constitutively active mu-
tant, or Rac1-T17N, the dominant negative mutant (Figure
5, D and E). Consistent with the whole-cell patch-clamp
analysis (Figure 4C), Rac1-G12V increased both the rate of
recovery and themobile fraction of TRPM6 (Figure 5, D and
E). Moreover, EGF treatment failed to increase further the
mobility or the mobile fraction. Conversely, a decreased
mobile fraction is observed in cells co-transfected with
Rac1-T17N. EGF treatment in the presence of Rac1-T17N
failed even to return themobile fraction of TRPM6 to that of
the control (Figure 5, D and E). These observations corre-
spond to decreased channel activity irrespective of EGF
treatment (Figure 4C). Furthermore, pretreatment with ei-
ther the EGFR antagonist AG1478 or the tyrosine kinase
receptor inhibitor RG13022 not only prevented the EGF-
mediated increase in mobile fraction of TRPM6 but also
decreased the baseline mobile fraction of the channel (Fig-
ure 5F). Taken together, these findings support the concept
that EGFR activation stimulates Rac1, alters cytoskeletal dy-
namics, and consequently increases the mobility of endo-
membrane TRPM6.
Given that TRPM6 current is enhanced by EGF treat-
ment together with the FRAP results, this suggests that en-
domembrane TRPM6 is moving into the plasmamembrane,
thereby increasing the number of active channels there. To
confirm that this was occurring, we performed cell surface
biotinylation experiments using the fused GFP for immu-
nodetection. We used a TRPM6 stably expressing the renal
epithelial cell line MDCK to perform these studies (referred
to hereafter as MDCK-GFP-TRPM6). Quantification of cell
surface expressed TRPM6 by this method revealed a signif-
icant increase in the cell surface expression of TRPM6 after
incubation with EGF (Figure 6).
Figure 5. EGF increases the mobility of TRPM6. (A) Immunoblot of GFP-TRPM6 transiently transfected
in HEK293 cells. (B) A confocal slice through a representative cell. (C) A plot of fluorescence recovery
over time in the presence (f) or absence (E) of EGF. (D) Similar curves of cells co-transfected with
GFP-TRPM6 and Rac1-G12V, Rac1-T17N, or mock in the presence or absence of EGF (, mock; ‚, mock
 EGF; , Rac1-G12V; *, Rac1-G12V  EGF; , Rac1-T17N; E, Rac1-T17N  EGF). (E) A histogram
displaying the final recovery of TRPM6 in the presence or absence of EGF when co-transfected with mock
(Control), Rac1-G12V, or Rac1-T17N as indicated. (F) A histogram displaying the final recovery of TRPM6
in the presence or absence of EGF after treatment with AG1478/tyrphostin (AG) or RG13022 (RG) as
indicated. *P  0.05 versus TRPM6 final recovery without EGF treatment in the presence of mock
co-transfection (n  14 to 21 cells).
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DISCUSSION
This study delineates the molecular details of TRPM6 stimula-
tion by EGF, from receptor to channel. First, we demonstrated
that EGF specifically activates TRPM6 via engagement of its
receptor, the EGFR.Weused a combination of live cell imaging
and biochemical and electrophysiologic approaches to eluci-
date the downstream signaling events. This revealed TRPM6
stimulation to be dependent on the activation of the Src family
of tyrosine kinases, the ERK/MEK pathway, and PI3K. Alter-
ations in endomembrane traffic were implicated as the respon-
sible mechanism because constitutively active Rac1 increased
TRPM6 current independent of EGF, whereas dominant neg-
ative Rac1 abrogated this effect. We further used FRAP to con-
firm that EGF increases themobility of TRPM6, an effect that is
alsoRac1 dependent.Ultimately, we showed that EGF activates
TRPM6 by increasing the number of channels at the plasma
membrane. Together, these findings clearly outline the activa-
tion of TRPM6 by EGF (Figure 6C), a process fundamental to
Mg2 homeostasis.
EGFR Signaling Pathway and TRP Channel Regulation
Our study is the first to demonstrate that EGF regulates the
melastatin subfamily of TRP channels. Furthermore, the effect
is specific to member TRPM6, because no increase in TRPM7
current, the closest homologue, was observed upon EGF appli-
cation. To confirm that EGF specifically activates the EGFR,we
demonstrated the presence of this receptor in our model sys-
tem and then showed an inhibition of the observed effect when
the receptor was blocked with selective antagonists. Further
evidence that EGFR engagement is required for TRPM6 acti-
vation was provided by the demonstration that inhibition of
the receptor’s tyrosine kinase activity pre-
vented both EGF-induced increase in
TRPM6 mobility and activity. Thus, EGF-
mediated activation of TRPM6 is novel
within this subfamily of channels and re-
quires the specific engagement of the
EGFR.
Among EGFR effectors, PLC is a
known regulator of TRPC channel activi-
ty.11,14 Furthermore, TRPM7 has been
shown to interact with PLC and  iso-
forms15 and to be inactivated by PIP2 hy-
drolysis16; however, inhibition of PLC
failed to prevent EGF-mediated TRPM6
regulation, suggesting that PLC is not nec-
essary for the activation of TRPM6 by EGF.
Thus, PLC is a potential discriminator be-
tween EGF regulation of TRPM6 and other
TRP channels.14,15 Furthermore, because
TRPM7 is activated by PLC and not EGF,
this finding highlights the specificity of the
EGF signaling cascade for TRPM6. Of note,
at80mV, the absolute current of TRPM6
is small and therefore likely represents a significant, albeit
small, leak current. Because of this, we used only the much
larger current at80 mV as a readout of channel activity.17
Inhibition of PI3K activity prevented EGF from activating
TRPM6. We therefore investigated the role of the small Rho
GTPase Rac1, a common effector of PI3K.18 Dominant nega-
tive Rac1 (T17N) abrogated TRPM6 current development and
prevented the EGF-mediated increase in TRPM6 activity. In
contrast, a constitutively active mutant of Rac1 (G12V) mim-
icked the EGF stimulation of TRPM6 activity. Both PI3K and
Rac1 components have been implicated in TRPC5 and TRPV1
stimulation upon EGF and nerve growth factor application,
respectively11,19; therefore, in addition to the regulation of
brain function such as neurite extension and pain perception
through TRP channels, our findings implicate Rac1 in renal
Mg2 reabsorption via the regulation of TRPM6 channel acti-
vation, independent of the constitutively expressed TRPM7.
Regulation of TRPM6 at the Plasma Membrane
The requirement of PI3K and Rac1 for EGF-mediated activa-
tion of TRPM6 suggests that altered endomembrane traffic
and potentially redistribution to the plasmamembrane are re-
sponsible for the increased current observed.20,21 To test this
hypothesis, we measured the mobility of TRPM6 before and
after treatment with EGF. This increased both the rate that
endomembrane TRPM6 was moving and the fraction that was
mobile. Indeed, the application of EGF seemed to mobilize an
immobile subset of TRPM6 (Figure 5, C, E, and F). The coex-
pression of Rac1 mutants altered the mobile fraction of
TRPM6, in parallel to the observed changes in activity. More-
over, coexpression of these constructs prevented the EGF-me-
diated alteration in TRPM6 mobility. Furthermore, applica-
Figure 6. EGF increases the cell surface fraction of TRPM6. (A) Representative
immunoblots of total cellular TRPM6, the input (top), and the biotinylated, cell surface
fraction (bottom) after treatment of GFP-TRPM6-MDCK cells with EGF (30 min, 10 nM)
or vehicle (Control). Nontransfected MDCK cells (Wild Type) and cells that were not
treated with biotin (No Biotin) are included for comparison. (B) Quantification of
experiment in A. *P  0.05 versus vehicle treated condition (n  11 per condition). (C)
EGFR stimulation by EGF leads to tyrosine kinase, Src, PI3K, and Rac1 activation. The
last effector alters the mobility of endomembrane TRPM6, potentially redistributing
the channel from within a storage compartment (SC) to a recycling endomembrane
compartment (RE). Ultimately, an increase in the plasma membrane insertion of TRPM6
is achieved and Mg2 influx through the channel is thereby increased.
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tion of the tyrosine kinase inhibitors produced changes in
TRPM6 mobility that were parallel to the alteration in activity
observed. That EGF activation ultimately leads to increased
expression at the plasma membrane was substantiated by cell
surface biotinylation analysis. Together, these observations
provide strong evidence that EGF increases the abundance of
TRPM6 at the plasma membrane.
What, then, explains the increased abundance of TRPM6 at
the plasma membrane? We propose that TRPM6 activation
subsequent to EGFR stimulation regulates the amount of recy-
cling TRPM6 and/or the balance between constitutive exocy-
tosis and endocytosis in favor of TRPM6 accumulation at the
cell surface. This hypothesis is supported by our FRAP analysis,
which demonstrates that EGFR activation increases themobil-
ity of endomembrane TRPM6 and releases a pool of immobile
or poorly mobile endomembrane channels. The total number
of channels within the plasmamembrane is determined by the
combined effects of membrane insertion, retrieval, and num-
ber of recycling channels. EGFR activation likely increases the
number of recycling channels and the balance between endo-
cytosis and exocytosis to favor increased plasma membrane
expression. Consistent with an effect of EGF on the recycling
kinetics of the TRP family of channels, EGF prevents the inter-
nalization of plasma membrane TRPC3.22
Potential Role(s) of EGF-Mediated Regulation of
TRPM6
Our findings implicate both Raf-1 and the ERK1/2 limb of the
MAPK superfamily in EGF-mediated activation of TRPM6.
EGF is known to alter ion homeostasis through inhibition of
the amiloride-sensitive Na reabsorption from collecting
duct. This also occurs downstream of ERK1/2 activation.23 In
kidney, TRPM6 and EGF are predominantly expressed in
DCT, the nephron segment responsible for regulated, transep-
ithelial Ca2 and Mg2 reabsorption.24 TRPM6 mediates and
regulates this latter process, a conclusion supported by its
unique permeation characteristics, carrying almost exclusively
divalent cations with a higher affinity for Mg2 than Ca25,25
and its specific localization to Mg2-transporting epithelia.
That this process is regulated by the MAPK is consistent with
previous findings; however, in DCT, EGF seems to activate
TRPM6 uniquely, to the exclusion of TRPM7, TRPV5, and
TRPV6 (Figure 2C; data not shown). TRPV5 mediates active
transcellular Ca2 reabsorption from the distal part of the
nephron; hence, EGFR signaling confers a precision to the con-
trol of Mg2 homeostasis and can therefore be defined as a
magnesiotropic hormone.
The specificity of this pathway is highlighted by clinical ex-
amples. The patient we originally described1 displayed clinical
symptoms secondary to hypomagnesemia and lacked evidence
of altered Ca2 homeostasis. Furthermore, treatment with the
anti-EGFR antibody cetuximab specifically alters plasma
Mg2 levels.1,3 The work described herein delineates the path-
way between EGFR engagement and apical Mg2 influx
throughTRPM6, a process whose specificity ismediated by the
restricted location of TRPM6 to the EGF-expressing portion of
the nephron and unique signaling within this location. This, in
turn, provides specificity to the maintenance of Mg2 ho-
meostasis. Both the Src family of tyrosine kinases and the small
Rho GTPase Rac1 are central to this. The increased activity of
TRPM6 is ultimately the result of increased cell surface expres-
sion. These findings provide molecular insight into a novel
mechanism specifically regulating transepithelial Mg2 trans-
port and consequently whole-body Mg2 homeostasis.
CONCISE METHODS
Cell Culture and Transfection
HEK293 cells were cultured in DMEMwith 10% FCS and transfected
as described previously.25 Electrophysiologic recordings, live cell im-
aging, and biochemical assays were performed 48 h after transfection.
MDCK cells were maintained in DMEM with 10% FCS. MDCK cells
were stably transfected with GFP-TRPM6, generated by subcloning
TRPM6 into the GFP vector as detailed online. To select a stable line
(MDCK-GFP-TRPM6), we cloned the cells by limiting dilution in the
presence of 500 g/ml G418 and screened them by immunofluores-
cence and immunoblotting for expression of GFP-tagged TRPM6.
The experiments were performed at least 72 h after the monolayers
had reached confluence.
Electrophysiology
We made electrophysiologic recordings 48 h after transfection of
HEK293 cells. We measured whole-cell currents with an EPC-10 am-
plifier (HEKA, Lambrecht, Germany); electrode resistances were 3 to
5 M	, and we monitored capacitance and access resistances contin-
uously. Please refer to additional on-line information about patch-
clamp experiments.
Fluorescence Recovery after Photobleaching
The experiments used a similar approach to that described previ-
ously.26 A detailed description of the method is available on-line.
Cell Surface Biotinylation
We incubated MDCK-GFP-TRPM6 cells at 37°C in the presence or
absence of EGF (10 nM, 30min) before placing them on ice to inhibit
endo- and exocytosis. We performed biotinylation on ice and lysed
cells as described previously.7 Subsequently, cell surface proteins were
precipitated with neutravidin-agarose beads. We probed the purified
biotinylated surface proteins for the presence of TRPM6 by immuno-
blotting with an anti-GFP antibody (Sigma-Aldrich, St. Louis, MO).
Statistical Analysis
Values are expressed asmeans SEM. Statistical significance between
groups was determined by ANOVA followed by pair-wise compari-
son using the method of Scheffe´. Differences in means with P 0.05
were considered statistically significant. The statistical analysis was
performed using the SPSS software (SPSS, Chicago, IL). Detailed de-
scriptions of Concise Methods are available on-line.
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